Virpax Pharmaceuticals, Inc.
Virpax Pharmaceuticals, Inc. (VRPX) Stock Competitors & Peer Comparison
See (VRPX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VRPX | $0.00 | -99.10% | 124 | N/A | -$71.00 | N/A |
| VRTX | $453.74 | -0.27% | 115.2B | 29.66 | $15.30 | N/A |
| REGN | $756.73 | +0.97% | 78.6B | 18.26 | $41.45 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ALNY | $328.16 | -0.16% | 43.5B | 140.24 | $2.34 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $692.83 | -0.61% | 42.9B | 35.64 | $19.44 | N/A |
| INSM | $147.60 | -0.48% | 31.8B | -22.99 | -$6.42 | N/A |
| UTHR | $532.53 | -1.67% | 23.3B | 19.13 | $27.84 | N/A |
| BNTX | $87.46 | -1.48% | 22B | -16.05 | -$5.45 | N/A |
Stock Comparison
VRPX vs VRTX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, VRTX has a market cap of 115.2B. Regarding current trading prices, VRPX is priced at $0.00, while VRTX trades at $453.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is 29.66. In terms of profitability, VRPX's ROE is +3.64%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, VRPX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check VRTX's competition here
VRPX vs REGN Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, VRPX is priced at $0.00, while REGN trades at $756.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 18.26. In terms of profitability, VRPX's ROE is +3.64%, compared to REGN's ROE of +0.15%. Regarding short-term risk, VRPX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check REGN's competition here
VRPX vs VRNA Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, VRPX is priced at $0.00, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -102.80. In terms of profitability, VRPX's ROE is +3.64%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, VRPX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check VRNA's competition here
VRPX vs ALNY Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, ALNY has a market cap of 43.5B. Regarding current trading prices, VRPX is priced at $0.00, while ALNY trades at $328.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is 140.24. In terms of profitability, VRPX's ROE is +3.64%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, VRPX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check ALNY's competition here
VRPX vs SGEN Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, VRPX is priced at $0.00, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, VRPX's ROE is +3.64%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, VRPX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check SGEN's competition here
VRPX vs ARGX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, ARGX has a market cap of 42.9B. Regarding current trading prices, VRPX is priced at $0.00, while ARGX trades at $692.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 35.64. In terms of profitability, VRPX's ROE is +3.64%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, VRPX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check ARGX's competition here
VRPX vs INSM Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, INSM has a market cap of 31.8B. Regarding current trading prices, VRPX is priced at $0.00, while INSM trades at $147.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas INSM's P/E ratio is -22.99. In terms of profitability, VRPX's ROE is +3.64%, compared to INSM's ROE of -1.68%. Regarding short-term risk, VRPX is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check INSM's competition here
VRPX vs UTHR Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, UTHR has a market cap of 23.3B. Regarding current trading prices, VRPX is priced at $0.00, while UTHR trades at $532.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 19.13. In terms of profitability, VRPX's ROE is +3.64%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, VRPX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check UTHR's competition here
VRPX vs BNTX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, BNTX has a market cap of 22B. Regarding current trading prices, VRPX is priced at $0.00, while BNTX trades at $87.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -16.05. In terms of profitability, VRPX's ROE is +3.64%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, VRPX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check BNTX's competition here
VRPX vs MRNA Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, MRNA has a market cap of 21.2B. Regarding current trading prices, VRPX is priced at $0.00, while MRNA trades at $53.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -7.38. In terms of profitability, VRPX's ROE is +3.64%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, VRPX is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check MRNA's competition here
VRPX vs BGNE Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, VRPX is priced at $0.00, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, VRPX's ROE is +3.64%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, VRPX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check BGNE's competition here
VRPX vs RPRX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, RPRX has a market cap of 20.1B. Regarding current trading prices, VRPX is priced at $0.00, while RPRX trades at $46.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 26.37. In terms of profitability, VRPX's ROE is +3.64%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, VRPX is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check RPRX's competition here
VRPX vs ROIV Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, ROIV has a market cap of 19.6B. Regarding current trading prices, VRPX is priced at $0.00, while ROIV trades at $27.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -22.98. In terms of profitability, VRPX's ROE is +3.64%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, VRPX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check ROIV's competition here
VRPX vs DNA-WT Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, VRPX is priced at $0.00, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, VRPX's ROE is +3.64%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, VRPX is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check DNA-WT's competition here
VRPX vs RVMD Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, RVMD has a market cap of 18.5B. Regarding current trading prices, VRPX is priced at $0.00, while RVMD trades at $93.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -15.67. In terms of profitability, VRPX's ROE is +3.64%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, VRPX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check RVMD's competition here
VRPX vs INCY Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, INCY has a market cap of 18.4B. Regarding current trading prices, VRPX is priced at $0.00, while INCY trades at $92.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 14.39. In terms of profitability, VRPX's ROE is +3.64%, compared to INCY's ROE of +0.29%. Regarding short-term risk, VRPX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check INCY's competition here
VRPX vs GMAB Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, GMAB has a market cap of 16.1B. Regarding current trading prices, VRPX is priced at $0.00, while GMAB trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 16.90. In terms of profitability, VRPX's ROE is +3.64%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, VRPX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check GMAB's competition here
VRPX vs BBIO Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, BBIO has a market cap of 14.1B. Regarding current trading prices, VRPX is priced at $0.00, while BBIO trades at $72.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -19.20. In terms of profitability, VRPX's ROE is +3.64%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, VRPX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check BBIO's competition here
VRPX vs ASND Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, ASND has a market cap of 13.5B. Regarding current trading prices, VRPX is priced at $0.00, while ASND trades at $220.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -51.16. In terms of profitability, VRPX's ROE is +3.64%, compared to ASND's ROE of +1.28%. Regarding short-term risk, VRPX is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check ASND's competition here
VRPX vs SMMT Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, SMMT has a market cap of 12.8B. Regarding current trading prices, VRPX is priced at $0.00, while SMMT trades at $17.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -11.99. In terms of profitability, VRPX's ROE is +3.64%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, VRPX is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check SMMT's competition here
VRPX vs KRTX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, VRPX is priced at $0.00, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, VRPX's ROE is +3.64%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, VRPX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check KRTX's competition here
VRPX vs IONS Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, IONS has a market cap of 12.3B. Regarding current trading prices, VRPX is priced at $0.00, while IONS trades at $74.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -31.19. In terms of profitability, VRPX's ROE is +3.64%, compared to IONS's ROE of -0.69%. Regarding short-term risk, VRPX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check IONS's competition here
VRPX vs MDGL Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, VRPX is priced at $0.00, while MDGL trades at $518.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -40.34. In terms of profitability, VRPX's ROE is +3.64%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, VRPX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check MDGL's competition here
VRPX vs JAZZ Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, JAZZ has a market cap of 11.6B. Regarding current trading prices, VRPX is priced at $0.00, while JAZZ trades at $189.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is -32.33. In terms of profitability, VRPX's ROE is +3.64%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, VRPX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check JAZZ's competition here
VRPX vs EXEL Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, EXEL has a market cap of 11.4B. Regarding current trading prices, VRPX is priced at $0.00, while EXEL trades at $42.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 15.24. In terms of profitability, VRPX's ROE is +3.64%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, VRPX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check EXEL's competition here
VRPX vs RNAM Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, VRPX is priced at $0.00, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas RNAM's P/E ratio is -17.39. In terms of profitability, VRPX's ROE is +3.64%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, VRPX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check RNAM's competition here
VRPX vs BMRN Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, BMRN has a market cap of 10.7B. Regarding current trading prices, VRPX is priced at $0.00, while BMRN trades at $55.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 30.86. In terms of profitability, VRPX's ROE is +3.64%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, VRPX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check BMRN's competition here
VRPX vs RXDX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, VRPX is priced at $0.00, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, VRPX's ROE is +3.64%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, VRPX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check RXDX's competition here
VRPX vs IMGN Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, VRPX is priced at $0.00, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, VRPX's ROE is +3.64%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, VRPX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check IMGN's competition here
VRPX vs ARWR Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, ARWR has a market cap of 8.5B. Regarding current trading prices, VRPX is priced at $0.00, while ARWR trades at $60.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is 38.01. In terms of profitability, VRPX's ROE is +3.64%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, VRPX is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check ARWR's competition here
VRPX vs AXSM Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, AXSM has a market cap of 8.4B. Regarding current trading prices, VRPX is priced at $0.00, while AXSM trades at $164.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -44.78. In terms of profitability, VRPX's ROE is +3.64%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, VRPX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check AXSM's competition here
VRPX vs BPMC Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, VRPX is priced at $0.00, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.58. In terms of profitability, VRPX's ROE is +3.64%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, VRPX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check BPMC's competition here
VRPX vs TECH Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, TECH has a market cap of 8.2B. Regarding current trading prices, VRPX is priced at $0.00, while TECH trades at $52.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 99.43. In terms of profitability, VRPX's ROE is +3.64%, compared to TECH's ROE of +0.04%. Regarding short-term risk, VRPX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check TECH's competition here
VRPX vs CERE Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, VRPX is priced at $0.00, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, VRPX's ROE is +3.64%, compared to CERE's ROE of -0.72%. Regarding short-term risk, VRPX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check CERE's competition here
VRPX vs PCVX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, PCVX has a market cap of 7.9B. Regarding current trading prices, VRPX is priced at $0.00, while PCVX trades at $54.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -9.72. In terms of profitability, VRPX's ROE is +3.64%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, VRPX is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check PCVX's competition here
VRPX vs CYTK Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, CYTK has a market cap of 7.8B. Regarding current trading prices, VRPX is priced at $0.00, while CYTK trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -9.71. In terms of profitability, VRPX's ROE is +3.64%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, VRPX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check CYTK's competition here
VRPX vs IBRX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, IBRX has a market cap of 7.6B. Regarding current trading prices, VRPX is priced at $0.00, while IBRX trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -19.42. In terms of profitability, VRPX's ROE is +3.64%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, VRPX is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check IBRX's competition here
VRPX vs HALO Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, HALO has a market cap of 7.5B. Regarding current trading prices, VRPX is priced at $0.00, while HALO trades at $63.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 24.72. In terms of profitability, VRPX's ROE is +3.64%, compared to HALO's ROE of +0.93%. Regarding short-term risk, VRPX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check HALO's competition here
VRPX vs MTSR Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, VRPX is priced at $0.00, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -23.58. In terms of profitability, VRPX's ROE is +3.64%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, VRPX is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check MTSR's competition here
VRPX vs KRYS Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, KRYS has a market cap of 7.3B. Regarding current trading prices, VRPX is priced at $0.00, while KRYS trades at $251.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 36.81. In terms of profitability, VRPX's ROE is +3.64%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, VRPX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check KRYS's competition here
VRPX vs ABVX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, ABVX has a market cap of 7.2B. Regarding current trading prices, VRPX is priced at $0.00, while ABVX trades at $109.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas ABVX's P/E ratio is -19.53. In terms of profitability, VRPX's ROE is +3.64%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, VRPX is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check ABVX's competition here
VRPX vs NUVL Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, NUVL has a market cap of 7.2B. Regarding current trading prices, VRPX is priced at $0.00, while NUVL trades at $98.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -16.76. In terms of profitability, VRPX's ROE is +3.64%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, VRPX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check NUVL's competition here
VRPX vs MRUS Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, VRPX is priced at $0.00, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -17.05. In terms of profitability, VRPX's ROE is +3.64%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, VRPX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check MRUS's competition here
VRPX vs ACLX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, VRPX is priced at $0.00, while ACLX trades at $114.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -28.17. In terms of profitability, VRPX's ROE is +3.64%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, VRPX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check ACLX's competition here
VRPX vs RETA Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, VRPX is priced at $0.00, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, VRPX's ROE is +3.64%, compared to RETA's ROE of +0.47%. Regarding short-term risk, VRPX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check RETA's competition here
VRPX vs KYMR Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, KYMR has a market cap of 6.5B. Regarding current trading prices, VRPX is priced at $0.00, while KYMR trades at $80.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -21.73. In terms of profitability, VRPX's ROE is +3.64%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, VRPX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check KYMR's competition here
VRPX vs PTGX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, PTGX has a market cap of 6.5B. Regarding current trading prices, VRPX is priced at $0.00, while PTGX trades at $102.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is -49.84. In terms of profitability, VRPX's ROE is +3.64%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, VRPX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check PTGX's competition here
VRPX vs PRAX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, PRAX has a market cap of 6.4B. Regarding current trading prices, VRPX is priced at $0.00, while PRAX trades at $302.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas PRAX's P/E ratio is -22.47. In terms of profitability, VRPX's ROE is +3.64%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, VRPX is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check PRAX's competition here
VRPX vs COGT Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, COGT has a market cap of 6B. Regarding current trading prices, VRPX is priced at $0.00, while COGT trades at $36.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas COGT's P/E ratio is -17.07. In terms of profitability, VRPX's ROE is +3.64%, compared to COGT's ROE of -1.00%. Regarding short-term risk, VRPX is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check COGT's competition here
VRPX vs BLTE Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, VRPX is priced at $0.00, while BLTE trades at $149.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas BLTE's P/E ratio is -64.52. In terms of profitability, VRPX's ROE is +3.64%, compared to BLTE's ROE of -0.43%. Regarding short-term risk, VRPX is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check BLTE's competition here
VRPX vs CGON Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, CGON has a market cap of 5.6B. Regarding current trading prices, VRPX is priced at $0.00, while CGON trades at $66.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -32.53. In terms of profitability, VRPX's ROE is +3.64%, compared to CGON's ROE of -0.23%. Regarding short-term risk, VRPX is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check CGON's competition here
VRPX vs CDTX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, VRPX is priced at $0.00, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas CDTX's P/E ratio is -19.77. In terms of profitability, VRPX's ROE is +3.64%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, VRPX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check CDTX's competition here
VRPX vs RYTM Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, RYTM has a market cap of 5.6B. Regarding current trading prices, VRPX is priced at $0.00, while RYTM trades at $81.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -26.33. In terms of profitability, VRPX's ROE is +3.64%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, VRPX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check RYTM's competition here
VRPX vs PTCT Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, VRPX is priced at $0.00, while PTCT trades at $67.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is 7.81. In terms of profitability, VRPX's ROE is +3.64%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, VRPX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check PTCT's competition here
VRPX vs ABCM Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, VRPX is priced at $0.00, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, VRPX's ROE is +3.64%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, VRPX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check ABCM's competition here
VRPX vs ISEE Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, VRPX is priced at $0.00, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, VRPX's ROE is +3.64%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, VRPX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check ISEE's competition here
VRPX vs FBIOX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, VRPX is priced at $0.00, while FBIOX trades at $24.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas FBIOX's P/E ratio is N/A. In terms of profitability, VRPX's ROE is +3.64%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, VRPX is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check FBIOX's competition here
VRPX vs CELC Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, CELC has a market cap of 5.3B. Regarding current trading prices, VRPX is priced at $0.00, while CELC trades at $114.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas CELC's P/E ratio is -31.20. In terms of profitability, VRPX's ROE is +3.64%, compared to CELC's ROE of -2.03%. Regarding short-term risk, VRPX is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check CELC's competition here
VRPX vs CAI Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, CAI has a market cap of 5.2B. Regarding current trading prices, VRPX is priced at $0.00, while CAI trades at $18.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas CAI's P/E ratio is -5.69. In terms of profitability, VRPX's ROE is +3.64%, compared to CAI's ROE of +0.25%. Regarding short-term risk, VRPX is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check CAI's competition here
VRPX vs IMVT Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, IMVT has a market cap of 5.2B. Regarding current trading prices, VRPX is priced at $0.00, while IMVT trades at $25.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -9.16. In terms of profitability, VRPX's ROE is +3.64%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, VRPX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check IMVT's competition here
VRPX vs TGTX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, TGTX has a market cap of 5.1B. Regarding current trading prices, VRPX is priced at $0.00, while TGTX trades at $31.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 11.55. In terms of profitability, VRPX's ROE is +3.64%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, VRPX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check TGTX's competition here
VRPX vs SRRK Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, SRRK has a market cap of 5.1B. Regarding current trading prices, VRPX is priced at $0.00, while SRRK trades at $44.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -13.44. In terms of profitability, VRPX's ROE is +3.64%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, VRPX is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check SRRK's competition here
VRPX vs ALKS Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, ALKS has a market cap of 5B. Regarding current trading prices, VRPX is priced at $0.00, while ALKS trades at $29.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 20.93. In terms of profitability, VRPX's ROE is +3.64%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, VRPX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check ALKS's competition here
VRPX vs TERN Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, VRPX is priced at $0.00, while TERN trades at $53.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas TERN's P/E ratio is -52.13. In terms of profitability, VRPX's ROE is +3.64%, compared to TERN's ROE of -0.30%. Regarding short-term risk, VRPX is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check TERN's competition here
VRPX vs ERAS Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, ERAS has a market cap of 4.7B. Regarding current trading prices, VRPX is priced at $0.00, while ERAS trades at $15.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas ERAS's P/E ratio is -34.45. In terms of profitability, VRPX's ROE is +3.64%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, VRPX is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check ERAS's competition here
VRPX vs XENE Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, VRPX is priced at $0.00, while XENE trades at $55.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -12.74. In terms of profitability, VRPX's ROE is +3.64%, compared to XENE's ROE of -0.56%. Regarding short-term risk, VRPX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check XENE's competition here
VRPX vs CRSP Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, VRPX is priced at $0.00, while CRSP trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -7.35. In terms of profitability, VRPX's ROE is +3.64%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, VRPX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check CRSP's competition here
VRPX vs FOLD Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, VRPX is priced at $0.00, while FOLD trades at $14.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas FOLD's P/E ratio is -160.33. In terms of profitability, VRPX's ROE is +3.64%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, VRPX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check FOLD's competition here
VRPX vs AKRO Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, VRPX is priced at $0.00, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -14.57. In terms of profitability, VRPX's ROE is +3.64%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, VRPX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check AKRO's competition here
VRPX vs MIRM Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, MIRM has a market cap of 4.5B. Regarding current trading prices, VRPX is priced at $0.00, while MIRM trades at $88.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -189.11. In terms of profitability, VRPX's ROE is +3.64%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, VRPX is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check MIRM's competition here
VRPX vs ALPN Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, VRPX is priced at $0.00, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, VRPX's ROE is +3.64%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, VRPX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check ALPN's competition here
VRPX vs APGE Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, APGE has a market cap of 4.3B. Regarding current trading prices, VRPX is priced at $0.00, while APGE trades at $78.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -20.15. In terms of profitability, VRPX's ROE is +3.64%, compared to APGE's ROE of -0.37%. Regarding short-term risk, VRPX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check APGE's competition here
VRPX vs OPT Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, VRPX is priced at $0.00, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, VRPX's ROE is +3.64%, compared to OPT's ROE of +0.88%. Regarding short-term risk, VRPX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check OPT's competition here
VRPX vs MRTX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, VRPX is priced at $0.00, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, VRPX's ROE is +3.64%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, VRPX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check MRTX's competition here
VRPX vs CORT Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, CORT has a market cap of 4.1B. Regarding current trading prices, VRPX is priced at $0.00, while CORT trades at $38.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 47.01. In terms of profitability, VRPX's ROE is +3.64%, compared to CORT's ROE of +0.15%. Regarding short-term risk, VRPX is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check CORT's competition here
VRPX vs LGND Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, LGND has a market cap of 4.1B. Regarding current trading prices, VRPX is priced at $0.00, while LGND trades at $203.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas LGND's P/E ratio is 33.23. In terms of profitability, VRPX's ROE is +3.64%, compared to LGND's ROE of +0.14%. Regarding short-term risk, VRPX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check LGND's competition here
VRPX vs VKTX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, VRPX is priced at $0.00, while VKTX trades at $34.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -10.74. In terms of profitability, VRPX's ROE is +3.64%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, VRPX is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check VKTX's competition here
VRPX vs CNTA Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, CNTA has a market cap of 4B. Regarding current trading prices, VRPX is priced at $0.00, while CNTA trades at $29.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas CNTA's P/E ratio is -15.39. In terms of profitability, VRPX's ROE is +3.64%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, VRPX is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check CNTA's competition here
VRPX vs CRNX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, CRNX has a market cap of 3.8B. Regarding current trading prices, VRPX is priced at $0.00, while CRNX trades at $36.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -7.34. In terms of profitability, VRPX's ROE is +3.64%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, VRPX is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check CRNX's competition here
VRPX vs RYZB Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, VRPX is priced at $0.00, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, VRPX's ROE is +3.64%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, VRPX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check RYZB's competition here
VRPX vs CBAY Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, VRPX is priced at $0.00, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, VRPX's ROE is +3.64%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, VRPX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check CBAY's competition here
VRPX vs ACAD Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, VRPX is priced at $0.00, while ACAD trades at $21.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 9.34. In terms of profitability, VRPX's ROE is +3.64%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, VRPX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check ACAD's competition here
VRPX vs NAMS Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, VRPX is priced at $0.00, while NAMS trades at $31.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas NAMS's P/E ratio is -18.17. In terms of profitability, VRPX's ROE is +3.64%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, VRPX is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check NAMS's competition here
VRPX vs SWTX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, VRPX is priced at $0.00, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas SWTX's P/E ratio is -13.78. In terms of profitability, VRPX's ROE is +3.64%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, VRPX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check SWTX's competition here
VRPX vs KNSA Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, KNSA has a market cap of 3.5B. Regarding current trading prices, VRPX is priced at $0.00, while KNSA trades at $46.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 62.37. In terms of profitability, VRPX's ROE is +3.64%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, VRPX is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check KNSA's competition here
VRPX vs EWTX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, EWTX has a market cap of 3.4B. Regarding current trading prices, VRPX is priced at $0.00, while EWTX trades at $31.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas EWTX's P/E ratio is -19.42. In terms of profitability, VRPX's ROE is +3.64%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, VRPX is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check EWTX's competition here
VRPX vs LQDA Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, LQDA has a market cap of 3.2B. Regarding current trading prices, VRPX is priced at $0.00, while LQDA trades at $36.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is -45.96. In terms of profitability, VRPX's ROE is +3.64%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, VRPX is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check LQDA's competition here
VRPX vs LEGN Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, LEGN has a market cap of 3.2B. Regarding current trading prices, VRPX is priced at $0.00, while LEGN trades at $17.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -10.87. In terms of profitability, VRPX's ROE is +3.64%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, VRPX is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check LEGN's competition here
VRPX vs DNTH Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, DNTH has a market cap of 3.2B. Regarding current trading prices, VRPX is priced at $0.00, while DNTH trades at $82.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas DNTH's P/E ratio is -23.56. In terms of profitability, VRPX's ROE is +3.64%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, VRPX is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check DNTH's competition here
VRPX vs DNLI Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, VRPX is priced at $0.00, while DNLI trades at $19.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas DNLI's P/E ratio is -6.65. In terms of profitability, VRPX's ROE is +3.64%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, VRPX is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check DNLI's competition here
VRPX vs ALMS Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, ALMS has a market cap of 3.1B. Regarding current trading prices, VRPX is priced at $0.00, while ALMS trades at $26.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas ALMS's P/E ratio is -9.20. In terms of profitability, VRPX's ROE is +3.64%, compared to ALMS's ROE of -0.73%. Regarding short-term risk, VRPX is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check ALMS's competition here
VRPX vs DYN Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, DYN has a market cap of 3.1B. Regarding current trading prices, VRPX is priced at $0.00, while DYN trades at $18.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas DYN's P/E ratio is -5.35. In terms of profitability, VRPX's ROE is +3.64%, compared to DYN's ROE of -0.61%. Regarding short-term risk, VRPX is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check DYN's competition here
VRPX vs TLX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, TLX has a market cap of 3B. Regarding current trading prices, VRPX is priced at $0.00, while TLX trades at $8.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas TLX's P/E ratio is -448.50. In terms of profitability, VRPX's ROE is +3.64%, compared to TLX's ROE of -0.02%. Regarding short-term risk, VRPX is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check TLX's competition here
VRPX vs CPRX Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, CPRX has a market cap of 3B. Regarding current trading prices, VRPX is priced at $0.00, while CPRX trades at $24.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 14.43. In terms of profitability, VRPX's ROE is +3.64%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, VRPX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check CPRX's competition here
VRPX vs VERA Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, VRPX is priced at $0.00, while VERA trades at $40.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas VERA's P/E ratio is -8.64. In terms of profitability, VRPX's ROE is +3.64%, compared to VERA's ROE of -0.60%. Regarding short-term risk, VRPX is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check VERA's competition here
VRPX vs SYRE Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, SYRE has a market cap of 2.9B. Regarding current trading prices, VRPX is priced at $0.00, while SYRE trades at $47.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas SYRE's P/E ratio is -24.00. In terms of profitability, VRPX's ROE is +3.64%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, VRPX is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check SYRE's competition here
VRPX vs MORF Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, VRPX is priced at $0.00, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas MORF's P/E ratio is -14.88. In terms of profitability, VRPX's ROE is +3.64%, compared to MORF's ROE of -0.29%. Regarding short-term risk, VRPX is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check MORF's competition here
VRPX vs TARS Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, TARS has a market cap of 2.9B. Regarding current trading prices, VRPX is priced at $0.00, while TARS trades at $67.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas TARS's P/E ratio is -42.26. In terms of profitability, VRPX's ROE is +3.64%, compared to TARS's ROE of -0.20%. Regarding short-term risk, VRPX is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check TARS's competition here
VRPX vs MOR Comparison March 2026
VRPX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRPX stands at 124. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, VRPX is priced at $0.00, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRPX currently has a P/E ratio of N/A, whereas MOR's P/E ratio is -12.64. In terms of profitability, VRPX's ROE is +3.64%, compared to MOR's ROE of -1.84%. Regarding short-term risk, VRPX is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for VRPX.Check MOR's competition here